RE:9 dollar target by AltaCorp? Should be higher>>MissLeaf wrote: I would suggest that a nine dollar target is reserved at best. The potential here in the Canabra died space globally is not to be underestimated. The synergies that cardiol has in place or paramount at this time not to mention new alliances that they will be forming I’m sure as time goes on. The potential for mass revenues is tremendous as The demand for pure CBD should continue to grow on a global scale. Don’t get too focussed on the CBD distribution channels and revenues, think diastolic heart disease and glioblastoma breakthroughs. Their partnerships with the University of Alberta, the Houston Methodist DeBakery heart and vascular Centre and the TecSalud in Mexico are paramount and invaluable. We could be looking at a $20 stock here in 2019. This place is massive and as the dust settles, only the well-established big boys will remain. Cardiol Therapeutics is definitely one of them!
AltaCorp's success assumptions for CRDL's drug trails are fairly conservative. 0-10% max success rate. As the project moves along its key milestones, the probablilty of those figures increase.
On the retail business (CardiolRX) business - this trades at <3x Revenue which is reasonable. AltaCorp values the net Corp + Biotech business at $6 currently. $6 for properly valued Biotech unit + $5-6/sh for the Retail business = $11-12